Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 1:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 1,219 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Soft Tissue Clear all
Active, not recruiting No phase listed Observational

Study to Learn More About the Safety and Effectiveness of the Drug VITRAKVI During Routine Use in Patients With TRK Fusion Cancer Which is Locally Advanced or Spread From the Place Where it Started to Other Places in the Body

NCT04142437
View directory record Official record
Conditions
Locally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene Fusion
Interventions
larotrectinib(Vitrakvi, BAY2757556)
Drug
Lead sponsor
Bayer
Industry
Eligibility
Not listed
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
33
States / cities
Los Angeles, California • Newport Beach, California • Palo Alto, California + 28 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 27, 2026, 1:15 PM EDT
Not listed No phase listed Observational

NECROtizing Soft Tissue Infections and Their Scoring System

NCT05224817
View directory record Official record
Conditions
Necrosis
Interventions
Necrotizing soft tissue infections (NSTIs)
Other
Lead sponsor
Methodist Health System
Other
Eligibility
18 Years to 89 Years
Enrollment
1,010 participants
Timeline
2019 – 2023
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 4, 2022 · Synced Oct 27, 2026, 1:15 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Renuvion APR System When Used as an Adjunct Procedure In Gynecomastia Surgery

NCT05093049
View directory record Official record
Conditions
Gynecomastia
Interventions
Renuvion APR System, Gynecomastia Correction Surgery
Device · Procedure
Lead sponsor
Apyx Medical
Industry
Eligibility
18 Years to 75 Years · Male only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Feb 8, 2024 · Synced Oct 27, 2026, 1:15 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Early Mobilization Following Volar Locking Plate Fixation of Distal Radius Fractures

NCT05033938
View directory record Official record
Conditions
Distal Radius Fracture
Interventions
Early Mobilization Protocol, Late Mobilization Protocol
Procedure
Lead sponsor
Robert Wood Johnson Barnabas Health
Other
Eligibility
18 Years to 75 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Somerset, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 5, 2021 · Synced Oct 27, 2026, 1:15 PM EDT
Terminated Not applicable Interventional

Feasibility of Auricular Acupressure for Appetite and Weight in Patients With Stage II-IV Gastric, Esophageal, and Pancreatic Cancer

NCT05911243
View directory record Official record
Conditions
Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage II Gastric Cancer AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage IV Esophageal Adenocarcinoma AJCC v8, Clinical Stage IV Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
Interventions
Acupressure Therapy, Best Practice, Biospecimen Collection, Questionnaire Administration
Procedure · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 27, 2026, 1:15 PM EDT
Not listed Phase 2 Interventional

Interferon Alfa and Thalidomide in Treating Patients With Soft Tissue Sarcoma or Bone Sarcoma

NCT00026416
View directory record Official record
Conditions
Sarcoma
Interventions
recombinant interferon alfa, thalidomide, adjuvant therapy
Biological · Drug · Procedure
Lead sponsor
Herbert Irving Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 6, 2014 · Synced Oct 27, 2026, 1:15 PM EDT
Terminated Phase 2 Interventional

A Study of Palifosfamide Tris Plus Doxorubicin Versus Doxorubicin in Unresectable or Metastatic Soft-tissue Sarcoma

NCT00718484
View directory record Official record
Conditions
Soft Tissue Sarcoma
Interventions
Palifosfamide-Tris, Doxorubicin
Drug
Lead sponsor
Alaunos Therapeutics
Industry
Eligibility
18 Years to 120 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
18
States / cities
Santa Monica, California • Washington D.C., District of Columbia • Tampa, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 27, 2026, 1:15 PM EDT
Completed Phase 1Phase 2 Interventional

Chemotherapy, SU5416, Radiation Therapy, and Surgery in Treating Patients With Soft Tissue Sarcoma

NCT00023738
View directory record Official record
Conditions
Sarcoma
Interventions
filgrastim, dacarbazine, doxorubicin hydrochloride, ifosfamide, semaxanib, conventional surgery, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
207
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 163 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2013 · Synced Oct 27, 2026, 1:15 PM EDT
Completed Not applicable Interventional

Does Self-Soft Tissue Mobilization of Obturator Internus Reduce Pelvic Floor or Hip Dysfunction

NCT07114068
View directory record Official record
Conditions
Pelvic Floor Dysfunction, Hip Pain
Interventions
Self mobilization of Obturator Internus Muscle using wand
Other
Lead sponsor
George Fox University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Newberg, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 13, 2025 · Synced Oct 27, 2026, 1:15 PM EDT
Recruiting Not applicable Interventional

Efficacy of OneMark Device in Identifying Breast Cancer for Surgery and Surveillance

NCT07087691
View directory record Official record
Conditions
Breast Cancer
Interventions
OneMark device
Device
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Oct 27, 2026, 1:15 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Ventral or Inguinal Hernia, Robotically Repaired With OviTex Mesh

NCT04779918
View directory record Official record
Conditions
Hernia, Ventral, Hernia, Inguinal
Interventions
OviTex Reinforced Tissue Matrix
Device
Lead sponsor
Tela Bio Inc
Industry
Eligibility
21 Years and older
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2029
U.S. locations
10
States / cities
Mobile, Alabama • Denver, Colorado • Destin, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 27, 2026, 1:15 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Alveolar Ridge Preservation Procedures

NCT05419778
View directory record Official record
Conditions
Alveolar Ridge Preservation
Interventions
Osteogen plug®, MInerOss®
Device
Lead sponsor
University of Tennessee
Other
Eligibility
12 Years and older
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 8, 2022 · Synced Oct 27, 2026, 1:15 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Environmental Pollutants and the Risk of Soft Tissue Sarcoma: A Pilot Study

NCT00611078
View directory record Official record
Conditions
Soft Tissue Sarcoma
Interventions
Not listed
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 79 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 20, 2011 · Synced Oct 27, 2026, 1:15 PM EDT
Active, not recruiting Phase 2 Interventional

Irinotecan and Carboplatin as Upfront Window Therapy in Treating Patients With Newly Diagnosed Intermediate-Risk or High-Risk Rhabdomyosarcoma

NCT00077285
View directory record Official record
Conditions
Sarcoma
Interventions
filgrastim, carboplatin, cyclophosphamide, dexrazoxane hydrochloride, doxorubicin hydrochloride, etoposide, ifosfamide, irinotecan hydrochloride, vincristine sulfate, conventional surgery, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Up to 50 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 27, 2026, 1:15 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effects of IASTM and Proprioception

NCT03023943
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Instrument Assisted Soft Tissue Mobilization
Other
Lead sponsor
Youngstown State University
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Youngstown, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 10, 2020 · Synced Oct 27, 2026, 1:15 PM EDT
Completed No phase listed Observational

An Observational Study to Learn More About Treatment With Regorafenib in People With Advanced Gastrointestinal Stromal Tumors in the United States

NCT06321055
View directory record Official record
Conditions
Advanced Gastrointestinal Stromal Tumor
Interventions
Regorafenib (Stivarga, BAY73-4506)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Whippany, New Jersey
Source: ClinicalTrials.gov public record
Updated May 20, 2025 · Synced Oct 27, 2026, 1:15 PM EDT
Completed Not applicable Interventional

The Effect of a Reduced Noise Environment on the Response Time of the Anesthesia Provider

NCT03507855
View directory record Official record
Conditions
Noise Exposure
Interventions
Reduced noise, Normal
Other
Lead sponsor
Joshua Uffman
Other
Eligibility
Not listed
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 8, 2024 · Synced Oct 27, 2026, 1:15 PM EDT
Terminated Phase 1 Interventional

Eltrombopag for the Prevention of Chemotherapy Induced Thrombocytopenia

NCT01491594
View directory record Official record
Conditions
Sarcoma, Soft Tissue, Osteosarcoma, Neoplasms, Connective and Soft Tissue
Interventions
Eltrombopag
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 82 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 2, 2014 · Synced Oct 27, 2026, 1:15 PM EDT
Completed Phase 2 Interventional

Massage Therapy for Breast Cancer Treatment-Related Swelling of the Arms

NCT00058851
View directory record Official record
Conditions
Lymphedema
Interventions
Manual lymph drainage, Combined physiotherapy, Compression bandaging
Procedure
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
Not listed
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 19, 2009 · Synced Oct 27, 2026, 1:15 PM EDT
Completed Not applicable Interventional Results available

INSPIRE Trial for Skin and Soft Tissue Infections

NCT05423756
View directory record Official record
Conditions
Skin and Soft Tissue (SST) Infection
Interventions
Arm 1: Routine Care, Arm 2: INSPIRE Stewardship Bundle for Skin and Soft Tissue Infection
Other
Lead sponsor
Harvard Pilgrim Health Care
Other
Eligibility
18 Years and older
Enrollment
118,562 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
102
States / cities
Riverside, California • San Jose, California • Thousand Oaks, California + 80 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 27, 2026, 1:15 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Instrument Assisted Soft Tissue Mobilization on Healthy Tissue Regarding Range of Motion and Grip Strength

NCT06613022
View directory record Official record
Conditions
Healthy
Interventions
Instrument Assisted Soft Tissue Mobilization first Control second, Control first Instrument Assisted Soft Tissue Mobilization second
Other
Lead sponsor
Beth Marschner
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Minot, North Dakota
Source: ClinicalTrials.gov public record
Updated Sep 25, 2024 · Synced Oct 27, 2026, 1:15 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Study to Evaluate Bone and Gum Dimension Changes Around Dental Implants Placed in Different Positions in Bone.

NCT01759537
View directory record Official record
Conditions
Mouth, Edentulous
Interventions
Ankylos dental endosseous implants-Sub-crestal, Ankylos dental endosseous implants-Epi-crestal
Device
Lead sponsor
Dentsply International
Industry
Eligibility
18 Years to 70 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 29, 2022 · Synced Oct 27, 2026, 1:15 PM EDT
Completed Phase 2 Interventional Results available

Ipilimumab + Nivolumab + Cryotherapy in Metastatic or Locally Advanced Soft Tissue Sarcoma

NCT04118166
View directory record Official record
Conditions
Soft Tissue Sarcoma
Interventions
Ipilimumab, Cryoablation, Nivolumab
Drug · Procedure
Lead sponsor
Kristen Ganjoo
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced Oct 27, 2026, 1:15 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Everolimus in Combination With Imatinib in Patients With Glivec Refractory/Resistant Gastrointestinal Stromal Tumors

NCT01275222
View directory record Official record
Conditions
Gastrointestinal Stromal Tumors
Interventions
RAD001, Imatinib 600mg/day (Glevec is the brand name for imatinib), Imatinib 800mg/day (Glevec is the brand name for imatinib)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
3
States / cities
Boston, Massachusetts • New York, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 25, 2021 · Synced Oct 27, 2026, 1:15 PM EDT